Nefiracetam: what does this study show?
13 patients randomized in a double-blind trial to nefiracetam 900 mg daily or placebo for 12 weeks. Route is not specified in the abstract.
The primary apathy outcome did not differ significantly between groups at 12 weeks.
The authors identify the very small randomized sample as the main limitation. This null trial does not prove equivalence, and it does not support healthy-person enhancement.
These findings apply to the population and methods described above.
What might this mean, and what would change the interpretation?
The authors identify the very small randomized sample as the main limitation. This null trial does not prove equivalence, and it does not support healthy-person enhancement.
What would clarify this: Independent replication with clinically meaningful outcomes and longer safety follow-up.
Findings reviewed · abstract
Checked Sep 23, 2026 against the linked abstract. This reading note is not a formal risk-of-bias appraisal.